Stonegate Capital Partners Updates Coverage on Alpha Cognition Inc. (NASDAQ: ACOG) 2Q26
Download Report Here Alpha Cognition’s 2Q26 results showed continued expansion of the ZUNVEYL launch, with net product revenue increasing 71% q/q to $6.0M as bottles dispensed increased 37% to 8,294 and repeat prescribers increased 29% to 1,024. Commercial momentum occurred while downstream PBM implementation remained approximately 16%, with management indicating that demand growth continued into […]
Stonegate Updates Coverage on Burcon Nutrascience Corporation (TSX: BU) 1Q27
Download Report Here Burcon’s 1Q27 results show improving commercial traction, with revenue up 54% q/q and 273% y/y to $1.28M, active buying customers reaching 40, and repeat orders providing better visibility into recurring demand. The $1.76M inventory write-down obscured improving underlying plant economics, with the adjusted gross loss narrowing materially as Galesburg utilization scales. The […]
Stonegate Capital Partners Updates Coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) 2Q26
Download Report Here NeOnc’s 2Q26 update meaningfully strengthens the clinical setup, with NEO100 meeting its Phase 2a primary endpoint and generating a notable overall survival signal of 26.09 months versus the 6–9 months management cites for current salvage therapy. The favorable safety profile, at-home administration, and lack of major toxicities support the potential for NEO100 […]
Stonegate Capital Partners Updates Coverage on NU Skin Enterprises Inc. (NYSE: NUS) 2Q26
Download Report Here NUS’ 2Q26 results reflected a weaker near-term operating setup, with revenue of $320.1M below our $345.2M estimate as Nu Skin and Rhyz revenue declined 15.5% and 25.0% y/y, respectively. Management reduced FY26 revenue guidance to $1.28B-$1.35B and adjusted EPS to $0.70-$0.90, while pushing the India launch into 1H27 as it refines local […]
Stonegate Capital Partners Updates Coverage on Viemed Healthcare Inc. (NASDAQ: VMD) 2Q26
Download Report Here Viemed’s 2Q26 results strengthened the forward revenue profile, supported by record ventilator census growth and continued scaling across sleep, resupply, and women’s health. Revenue growth accelerated and cash generation improved, although a greater mix of lower-margin, less capital-intensive product and service revenue, alongside growth investments and temporary transition costs, pressured near-term profitability. […]